In this episode, Drs. Ahmad Masri and Kevin Alexander review emerging clinical data in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at the Heart Failure Society of America Annual Scientific Meeting and the American Heart Association Scientific Sessions 2025, including key findings from the ATTRibute-CM and HELIOS-B trials. The discussion highlights recent publications evaluating currently available disease-modifying therapies. Drs. Masri and Alexander translate these new data into practical insights for clinicians, focusing on how evolving evidence may influence treatment selection, therapeutic sequencing, and integration of disease-modifying therapies into everyday clinical practice.